银屑病关节炎疾病影响(PsAID)问卷的验证及其作为临床实践中单条目结局指标的潜力
本研究在前瞻性单中心银屑病关节炎队列中验证PsAID问卷,129例患者完成基线评估。PsAID12的组内相关系数为0.91(95%CI 0.87至0.94),标准化反应均数为0.74(95%CI 0.45至0.97),与多数患者报告结局指标强相关,各单条目与对应问卷强相关,可减少问卷负担。
要点
- PsAID12重测信度ICC为0.91(95%CI 0.87至0.94),测量标准误为0.51,最小可检测变化为1.41。
- PsAID12的标准化反应均数为0.74(95%CI 0.45至0.97),与多数患者报告结局指标强相关(r≥0.70)。
- 各单条目与对应患者报告结局问卷强相关(r≥0.67),有望减少问卷负担。
核心结论
- PsAID在银屑病关节炎患者中是一种可靠、可行且具有区分度的测量工具。
- PsAID良好的反应度及各单条目与其他患者报告结局指标的强相关,为研究和临床实践中减少问卷负担提供了机会。
研究设计与样本
- 前瞻性单中心银屑病关节炎患者队列研究。
- 共129例患者完成基线问卷和评估,平均年龄52.1±13.3岁,女性占57%,病程10.2±8年。
主要发现
- 基线PsAID12平均得分为3.92±2.26。
- PsAID12的组内相关系数为0.91(95%CI 0.87至0.94),测量标准误为0.51,最小可检测变化为1.41。
- PsAID12与多数患者报告结局指标强相关(r≥0.70),与临床结局指标中度相关(r=0.40-0.57)。
- 在活动性疾病需改变治疗的患者中,3个月时PsAID12的标准化反应均数为0.74(95%CI 0.45至0.97)。
- 各PsAID单条目与其对应的患者报告结局问卷强相关(r≥0.67)。
临床怎么用
- 原文结论认为PsAID可靠、可行且具有区分度,其良好反应度和单条目与其他患者报告结局指标的强相关,为减少问卷负担提供了机会。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire is a recently developed patient-reported outcome measure (PROM) of disease impact in psoriatic arthritis (PsA). We set out to assess the validity in an independent cohort of patients, estimate the minimally important difference for improvement and explore the potential of individual components of the PsAID in clinical practice. METHODS: Data were collected prospectively for a single-centre cohort of patients with PsA. Construct validity was assessed by Spearman correlation with other PROMs and reliability by intraclass correlation coefficient (ICC) at 1 week. Sensitivity to change at 3 months was determined by the standardised response mean (SRM) in those patients with active disease requiring a change in treatment. RESULTS: A total of 129 patients (mean ±SD age 52.1±13.3, 57% women, disease duration 10.2±8 years) completed the baseline questionnaires and assessments. The mean baseline PsAID12 score was 3.92±2.26 with an ICC of 0.91 (95%CI 0.87 to 0.94). The SE of measurement was 0.51 and the minimal detectable change was 1.41. There was strong correlation (r≥0.70) with most of the PROMs studied and moderate correlation with clinical outcomes (r=0.40-0.57). The SRM of the PsAID12 was 0.74 (95%CI 0.45 to 0.97). There was strong correlation with individual PsAID items and their corresponding PROM questionnaires (r≥0.67). CONCLUSION: The PsAID is a reliable, feasible and discriminative measure in patients with PsA. The good responsiveness of the PsAID and strong correlation of individual items with other PROMS represent an opportunity to reduce questionnaire burden for patients in studies and clinical practice.
引用
- Holland R, Tillett W, Korendowych E, et al. Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice. Ann Rheum Dis. 2017. PMID: 29146740. doi:10.1136/annrheumdis-2017-211996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。